Monday , September 26 2022

Can I inject millions of stem cells into Parkinson's disease?


A new experimental therapy for Parkinson's disease, which involves injecting millions of special stem cells into the brain of patients with conditions, is currently being tested in a clinical trial.

The study, which started in October, is carried out by researchers at the University of Kyoto, Japan. According to him, researchers began to treat one man in their fifties, according to AFP.

Although previous studies have tested stem cell therapy for Parkinson's disease, the new study is the first to use so-called induced pluripotent stem cells or iPSC. These are "adult" cells (such as blood cells or skin cells, unlike embryonic cells) reprogrammed to resemble early cells and have the potential to form any type of cell in the body.

For research, the researchers used iPSCs to create "dopaminergic progenitor" cells or cells that lead to brain cells that produce dopamine, brain chemicals needed to control muscle movement. In patients with Parkinson's disease, brain cells producing dopamine die, which leads to symptoms such as tremors and difficulties in walking, movement and coordination. [10 Things You Didn’t Know About the Brain]

In the new trial, the researchers hope to show that these transplanted stem cells will help to replace lost cells for the production of dopamine and restore the production of dopamine, according to the Michael J Foundation. Fok.

For treatment, the researchers injected 2.4 million stem cells to the left side of the human brain, in an operation that lasted 3 hours, according to AFP. The patient will now be monitored for side effects, and if there is no problem, the researchers will inject another 2.4 million stem cells into the right side of his brain.

The researchers plan to enroll a total of seven patients in the trial and monitor patients for two years.

IPSCs are derived from donors, so patients will have to take medication to suppress the immune system to prevent the rejection of transplanted cells, according to the University of Kyoto.

Originally published on Live Science.

Source link